Elanco Animal Health Incorporated (NYSE:ELAN) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Elanco Animal Health Incorporated (NYSE:ELAN) have been given a consensus recommendation of “Hold” by the seven research firms that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $17.43.

Several research firms have recently weighed in on ELAN. Barclays boosted their price target on Elanco Animal Health from $21.00 to $22.00 and gave the stock an “overweight” rating in a report on Monday, September 23rd. Morgan Stanley cut shares of Elanco Animal Health from an “overweight” rating to an “equal weight” rating and decreased their price target for the company from $17.00 to $15.00 in a research report on Thursday, September 19th. Stifel Nicolaus reiterated a “buy” rating and set a $20.00 price target on shares of Elanco Animal Health in a report on Thursday, September 19th. Finally, Piper Sandler lowered their target price on Elanco Animal Health from $19.00 to $16.00 and set a “neutral” rating for the company in a research report on Monday, July 1st.

Insider Buying and Selling

In other Elanco Animal Health news, CEO Jeffrey N. Simmons acquired 100,000 shares of the company’s stock in a transaction dated Monday, August 12th. The shares were bought at an average cost of $13.01 per share, with a total value of $1,301,000.00. Following the purchase, the chief executive officer now directly owns 145,000 shares of the company’s stock, valued at $1,886,450. This trade represents a 200.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CEO Jeffrey N. Simmons acquired 100,000 shares of Elanco Animal Health stock in a transaction dated Monday, August 12th. The stock was bought at an average price of $13.01 per share, with a total value of $1,301,000.00. Following the transaction, the chief executive officer now directly owns 145,000 shares in the company, valued at $1,886,450. This represents a 200.00 % increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Michael J. Harrington bought 3,500 shares of the company’s stock in a transaction that occurred on Thursday, August 22nd. The shares were bought at an average price of $14.85 per share, for a total transaction of $51,975.00. Following the transaction, the director now directly owns 81,094 shares in the company, valued at $1,204,245.90. This trade represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.57% of the stock is owned by insiders.

Institutional Trading of Elanco Animal Health

Several large investors have recently made changes to their positions in ELAN. Hunter Associates Investment Management LLC boosted its holdings in Elanco Animal Health by 5.1% in the first quarter. Hunter Associates Investment Management LLC now owns 16,600 shares of the company’s stock worth $269,000 after acquiring an additional 800 shares in the last quarter. 180 Wealth Advisors LLC grew its position in Elanco Animal Health by 3.6% in the 2nd quarter. 180 Wealth Advisors LLC now owns 25,716 shares of the company’s stock valued at $352,000 after purchasing an additional 893 shares during the period. HBK Sorce Advisory LLC increased its stake in Elanco Animal Health by 9.4% during the 2nd quarter. HBK Sorce Advisory LLC now owns 12,920 shares of the company’s stock valued at $186,000 after purchasing an additional 1,107 shares in the last quarter. Atomi Financial Group Inc. raised its holdings in Elanco Animal Health by 11.1% during the second quarter. Atomi Financial Group Inc. now owns 12,260 shares of the company’s stock worth $177,000 after buying an additional 1,221 shares during the last quarter. Finally, Keene & Associates Inc. lifted its stake in shares of Elanco Animal Health by 5.7% in the third quarter. Keene & Associates Inc. now owns 22,945 shares of the company’s stock valued at $337,000 after buying an additional 1,240 shares in the last quarter. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Elanco Animal Health Trading Up 0.2 %

ELAN opened at $12.41 on Friday. The company has a market cap of $6.13 billion, a P/E ratio of -4.87, a PEG ratio of 1.32 and a beta of 1.40. The company has a current ratio of 2.93, a quick ratio of 1.75 and a debt-to-equity ratio of 0.92. The company’s 50 day moving average is $14.32 and its 200-day moving average is $14.79. Elanco Animal Health has a 1-year low of $8.52 and a 1-year high of $18.80.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Thursday, August 8th. The company reported $0.30 earnings per share for the quarter, topping analysts’ consensus estimates of $0.24 by $0.06. Elanco Animal Health had a negative net margin of 27.94% and a positive return on equity of 7.29%. The firm had revenue of $1.18 billion for the quarter, compared to analysts’ expectations of $1.15 billion. During the same quarter in the previous year, the firm posted $0.18 earnings per share. The company’s revenue was up 12.0% on a year-over-year basis. Equities research analysts predict that Elanco Animal Health will post 0.91 earnings per share for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.